---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-170690"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:07:35.075185+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Director Jessie English resigns from Sensei Biotherapeutics board effective July 1, 2024

## Summary
- Jessie English, PhD notified Board of resignation on June 26, 2024, effective July 1, 2024.
- Resignation due to personal reasons; no disagreement with Company's operations, policies, or practices.
- No replacement named; Board size reduced to current members.

## SEC filing metadata
- accession: 0001193125-24-170690
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312524170690/0001193125-24-170690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312524170690/d117545d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-170690
- JSON: https://secwatch.observer/filing/0001193125-24-170690.json
- Plain text: https://secwatch.observer/filing/0001193125-24-170690.txt

## Key facts
- Executive change
  Jessie English resigned as Director at Sensei Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 26, 2024, Jessie English, PhD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312524170690/0001193125-24-170690-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.